GlassScriptPhysician profile
Sam S Chang
NPI 1922107358
$197,844.89
in general payments reported to CMS, 2019-2025
25 companies · $130K in 2025
The $130K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,411 · 2020: $6,890 · 2021: $12K · 2022: $15K · 2023: $13K · 2024: $12K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $127K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,788 · Travel and Lodging: $7,891 · Food and Beverage: $6,127 · Honoraria: $3,600 · Education: $6.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $127,242.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,787.50 |
| Travel and Lodging | $7,890.84 |
| Food and Beverage | $6,126.89 |
| Honoraria | $3,600.00 |
| Education | $6.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $107,922.94 | 2020-2025 | Jelmyto |
| Janssen Biotech, INC. | $18,370.28 | 2023-2025 | Carvykti, Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $16,269.47 | 2019-2023 | |
| Janssen Research & Development, LLC | $9,367.67 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $8,496.32 | 2023-2024 | Pylarify |
| Immunitybio, INC. | $8,034.49 | 2024-2025 | |
| Photocure INC | $6,618.71 | 2019-2025 | Cysview |
| Telix Pharmaceuticals | $4,637.64 | 2024-2025 | Illuccix |
| Janssen Scientific Affairs, LLC | $4,511.73 | 2022 | |
| Pfizer INC. | $3,515.79 | 2025 | |
| Ferring Pharmaceuticals INC. | $3,355.70 | 2024-2025 | Adstiladrin |
| Astellas Pharma Global Development | $1,755.00 | 2023 | Xtandi |
| Provepharm INC. | $1,606.60 | 2024 | Bludigo |
| Janssen Global Services, LLC | $1,050.45 | 2020-2023 | Agility |
| Bayer Healthcare Pharmaceuticals INC. | $516.09 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $505.00 | 2021 | |
| Genentech, INC. | $352.50 | 2024 | |
| Karl Storz Endoscopy-America | $222.38 | 2019-2022 | |
| Clovis Oncology, INC. | $140.22 | 2019-2020 | |
| Genzyme Corporation | $121.30 | 2022 | |
| Myovant Sciences INC. | $108.20 | 2021 | |
| Comsort, INC | $100.00 | 2019 | |
| Angiodynamics, INC. | $97.08 | 2022 | |
| Emd Serono, INC. | $86.56 | 2022 | |
| Seagen INC. | $82.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.